ArticleIn vivo (Athens, Greece)
Helical Tomotherapy in Local Advanced Breast Cancer Following Mastectomy: Long-term Results and Late Toxicity Analysis.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimAdjuvant radiotherapy is a key part of the overall treatment plan for local advanced breast cancer. In this study, we investigated the long-term clinical outcomes of helical tomotherapy (hT) following mastectomy. PATIENTS AND
methodsFemale patients (n=38) with locally advanced or lymph node-positive breast cancer who had undergone mastectomy, sentinel-node biopsy, and/or axillary lymph node dissection were included in this single-center analysis. Postmastectomy radiation therapy (PMRT) to involved chest wall was applied by using hT with cumulative dose of 50.4 Gy. Lymphatic drainage pathways were included when they contained tumor cells. Generally, additional mastectomy scar boost irradiation (10 Gy) was applied up to a cumulative dose of 60.4 Gy. Local control (LC), metastasis, survival, toxicity, and secondary malignancy rates were analyzed retrospectively.
resultsThe mean follow-up duration was 80 months. LC rates at 5 and 8 years were 97.2%, while metastasis-free survival (MFS) rates were 61.6% and 58%, respectively. Overall survival (OS) rates at 5 and 8 years were 83.9% and 66%, respectively. The occurrence of acute erythema was recorded in 60.5% (grades 1-2) and 23.7% (grade 3) of patients. 18.4% of treated patients developed grade 1 ipsilateral arm lymphedema and 5.3% grade 2. Serious adverse events, higher than grade 3, were not seen. Only one patient showed secondary malignancy 24 months after PMRT.
conclusionExcellent long-term results and low toxicity rates can be achieved in patients with locally advanced breast cancer by applying PMRT using hT. We are the first to report on the very low late toxicity rates and incidence of secondary malignancies. Our data suggests that broader clinical implementation of hT could benefit these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.